Ausgabe 3/2013
Inhalt (28 Artikel)
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses
Roman Rouzier, Paolo Pronzato, Elisabeth Chéreau, Josh Carlson, Barnaby Hunt, William J. Valentine
Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status
Gaiane M. Rauch, Henry M. Kuerer, Marion E. Scoggins, Patricia S. Fox, Ana P. Benveniste, Young Mi Park, Sara A. Lari, Brian P. Hobbs, Beatriz E. Adrada, Savitri Krishnamurthy, Wei T. Yang
CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
K. Beelen, M. Opdam, T. M. Severson, R. H. T. Koornstra, A. D. Vincent, M. Hauptmann, R. H. N. van Schaik, E. M. J. J. Berns, J. B. Vermorken, P. J. van Diest, S. C. Linn
T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity
Denise L. Cecil, Kyong Hwa Park, Ekram Gad, Jennifer S. Childs, Doreen M. Higgins, Stephen R. Plymate, Mary L. Disis
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
S. Muenst, S. D. Soysal, F. Gao, E. C. Obermann, D. Oertli, W. E Gillanders
Differential characteristics of heart, liver, and brain metastatic subsets of murine breast carcinoma
Nuray Erin, Şule Kale, Gamze Tanrıöver, Sadi Köksoy, Özlem Duymuş, Aylin F. Korcum
Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype
Hui Li, Sara Duhachek-Muggy, Suzanne Dubnicka, Anna Zolkiewska
BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence
Timothy M. D’Alfonso, Ryan K. van Laar, Linda T. Vahdat, Wasay Hussain, Rachel Flinchum, Nathan Brown, Linda Saint John, Sandra J. Shin
MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)
Xuyang Jiao, Lin Zhao, Mengtao Ma, Xuefeng Bai, Miao He, Yuanyuan Yan, Yan Wang, Qiuchen Chen, Xinnan Zhao, Mingyi Zhou, Zeshi Cui, Zhihong Zheng, Enhua Wang, Minjie Wei
Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism
Toru Hanamura, Toshifumi Niwa, Sayo Nishikawa, Hiromi Konno, Tatsuyuki Gohno, Chika Tazawa, Yasuhito Kobayashi, Masafumi Kurosumi, Hiroyuki Takei, Yuri Yamaguchi, Ken-ichi Ito, Shin-ichi Hayashi
HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients
Soo Youn Bae, Yoon La Choi, Sangmin Kim, Minkuk Kim, Jiyoung Kim, Seung Pil Jung, Min-Young Choi, Se Kyung Lee, Won Ho Kil, Jeong Eon Lee, Seok Jin Nam
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
J. Bjöhle, J. Bergqvist, J. S. Gronowitz, H. Johansson, L. Carlsson, Z. Einbeigi, B. Linderholm, N. Loman, M. Malmberg, M. Söderberg, M. Sundquist, T. M. Walz, M. Fernö, J. Bergh, T. Hatschek
Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy
Stefan Glück, Femke de Snoo, Justine Peeters, Lisette Stork-Sloots, George Somlo
Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention
Chris I. Flowers, Cristina O’Donoghue, Dan Moore, Adeline Goss, Danny Kim, June-Ho Kim, Sjoerd G. Elias, Julia Fridland, Laura J. Esserman
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Hans-Joachim Lück, Andreas Du Bois, Sibylle Loibl, Iris Schrader, Jens Huober, Volker Heilmann, Matthias Beckmann, Ann Stähler, Christian Jackisch, Michael Hubalek, Barbara Richter, Elmar Stickeler, Holger Eidtmann, Christoph Thomssen, Michael Untch, Kerstin Wollschläger, Tibor Schuster, Gunter von Minckwitz
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial
Lise Roca, Véronique Diéras, Henri Roché, Emmanuelle Lappartient, Pierre Kerbrat, Laurent Cany, Stéphanie Chieze, Jean-Luc Canon, Marc Spielmann, Frédérique Penault-Llorca, Anne-Laure Martin, Christel Mesleard, Jérôme Lemonnier, Patricia de Cremoux
Plasma enterolactone and breast cancer risk in the Nurses’ Health Study II
Jing Xie, Shelley S. Tworoger, Adrian A. Franke, Kathryn L. Terry, Megan S. Rice, Bernard A. Rosner, Walter C. Willett, Susan E. Hankinson, A. Heather Eliassen
Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands
A. Font-Gonzalez, L. Liu, A. C. Voogd, M. K. Schmidt, J. A. Roukema, J. W. W. Coebergh, E. de Vries, I. Soerjomataram
Breast cancer in postmenopausal women after non-melanomatous skin cancer: the Women’s Health Initiative observational study
Mary Pressler, Carol A. Rosenberg, Benjamin A. Derman, Philip Greenland, Janardan Khandekar, Rebecca J. Rodabough, Anne McTiernan, Michael S. Simon
Association of progesterone receptor gene (PGR) variants and breast cancer risk in African American women
Courtney A. Gabriel, Nandita Mitra, Angela DeMichele, Timothy Rebbeck
Prevalence and impact of correlative science in breast cancer phase II trials
Tian Zhang, Andrew Schneider, Erika P. Hamilton, Krish Patel, Arif H. Kamal, Gary H. Lyman, Jeffrey M. Peppercorn
Moderate-to-vigorous intensity physical activity across the life course and risk of pre- and post-menopausal breast cancer
Lindsay C. Kobayashi, Ian Janssen, Harriet Richardson, Agnes S. Lai, John J. Spinelli, Kristan J. Aronson
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting
Gary H. Lyman, David C. Dale, Dianne Tomita, Sadie Whittaker, Jeffrey Crawford
Case-only analyses of the associations between polymorphisms in the metastasis-modifying genes BRMS1 and SIPA1 and breast tumor characteristics, lymph node metastasis, and survival
Michelle R. Roberts, Chi-Chen Hong, Stephen B. Edge, Song Yao, Wiam Bshara, Michael J. Higgins, Jo L. Freudenheim, Christine B. Ambrosone
Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model
Gillian S. Dite, Maryam Mahmoodi, Adrian Bickerstaffe, Fleur Hammet, Robert J. Macinnis, Helen Tsimiklis, James G. Dowty, Carmel Apicella, Kelly-Anne Phillips, Graham G. Giles, Melissa C. Southey, John L. Hopper
Adherence to screening mammography among American Indian women of the northern plains
Emily L. Roen, Marilyn A. Roubidoux, Annette I. Joe, Tina R. Russell, Amr S. Soliman
ROCK: a resource for integrative breast cancer data analysis
Saif Ur-Rehman, Qiong Gao, Costas Mitsopoulos, Marketa Zvelebil
Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen
Lisette Binkhorst, Ron H. J. Mathijssen, Myrthe P. P. van Herk-Sukel, Marjolein Bannink, Agnes Jager, Erik A. C. Wiemer, Teun van Gelder